A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer

Bryan Oronsky, Carolyn M. Ray, Alexander Spira, Jane B. Trepel, Corey A. Carter, Hope M. Cottrill

Research output: Contribution to journalReview article

Abstract

Ovarian cancer, which ranks fifth in cancer deaths among women, is the most lethal gynecologic malignancy. Epithelial ovarian cancer (EOC) is the most common histologic type, with the 5-year survival for all stages estimated at 45.6%. This rate increases to more than 70% in the minority of patients who are diagnosed at an early stage, but declines to 35% in the vast majority of patients diagnosed at advanced stage. Recurrent EOC is incurable. Platinum sensitivity (or lack thereof) is a major determinant of prognosis. The current standard treatment is primary surgery followed by platinum-based chemotherapy. In recurrent platinum-resistant/platinum-refractory EOC, sequential single-agent salvage chemotherapy is superior to multiagent chemotherapy. Multiagent regimens increase toxicity without clear benefit; however, no preferred sequence of single agents is recommended. The impact of targeted therapies and immunotherapies on progression-free survival and overall survival, which remains dismal, is under active investigation. Currently, clinical trials offer the best hope for the development of a new treatment paradigm in this recalcitrant disease.

Original languageEnglish (US)
Article number103
JournalMedical Oncology
Volume34
Issue number6
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Fingerprint

Platinum
Ovarian Neoplasms
Drug Therapy
Survival
Immunotherapy
Disease-Free Survival
Neoplasms
Therapeutics
Clinical Trials
Ovarian epithelial cancer

Keywords

  • Epigenetic
  • Epithelial ovarian cancer
  • Platinum refractory
  • Platinum resistant
  • VEGF inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer. / Oronsky, Bryan; Ray, Carolyn M.; Spira, Alexander; Trepel, Jane B.; Carter, Corey A.; Cottrill, Hope M.

In: Medical Oncology, Vol. 34, No. 6, 103, 01.06.2017.

Research output: Contribution to journalReview article

Oronsky, Bryan ; Ray, Carolyn M. ; Spira, Alexander ; Trepel, Jane B. ; Carter, Corey A. ; Cottrill, Hope M. / A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer. In: Medical Oncology. 2017 ; Vol. 34, No. 6.
@article{61bd1d33fe124133b8a9be1c1434b25e,
title = "A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer",
abstract = "Ovarian cancer, which ranks fifth in cancer deaths among women, is the most lethal gynecologic malignancy. Epithelial ovarian cancer (EOC) is the most common histologic type, with the 5-year survival for all stages estimated at 45.6{\%}. This rate increases to more than 70{\%} in the minority of patients who are diagnosed at an early stage, but declines to 35{\%} in the vast majority of patients diagnosed at advanced stage. Recurrent EOC is incurable. Platinum sensitivity (or lack thereof) is a major determinant of prognosis. The current standard treatment is primary surgery followed by platinum-based chemotherapy. In recurrent platinum-resistant/platinum-refractory EOC, sequential single-agent salvage chemotherapy is superior to multiagent chemotherapy. Multiagent regimens increase toxicity without clear benefit; however, no preferred sequence of single agents is recommended. The impact of targeted therapies and immunotherapies on progression-free survival and overall survival, which remains dismal, is under active investigation. Currently, clinical trials offer the best hope for the development of a new treatment paradigm in this recalcitrant disease.",
keywords = "Epigenetic, Epithelial ovarian cancer, Platinum refractory, Platinum resistant, VEGF inhibitor",
author = "Bryan Oronsky and Ray, {Carolyn M.} and Alexander Spira and Trepel, {Jane B.} and Carter, {Corey A.} and Cottrill, {Hope M.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s12032-017-0960-z",
language = "English (US)",
volume = "34",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "6",

}

TY - JOUR

T1 - A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer

AU - Oronsky, Bryan

AU - Ray, Carolyn M.

AU - Spira, Alexander

AU - Trepel, Jane B.

AU - Carter, Corey A.

AU - Cottrill, Hope M.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Ovarian cancer, which ranks fifth in cancer deaths among women, is the most lethal gynecologic malignancy. Epithelial ovarian cancer (EOC) is the most common histologic type, with the 5-year survival for all stages estimated at 45.6%. This rate increases to more than 70% in the minority of patients who are diagnosed at an early stage, but declines to 35% in the vast majority of patients diagnosed at advanced stage. Recurrent EOC is incurable. Platinum sensitivity (or lack thereof) is a major determinant of prognosis. The current standard treatment is primary surgery followed by platinum-based chemotherapy. In recurrent platinum-resistant/platinum-refractory EOC, sequential single-agent salvage chemotherapy is superior to multiagent chemotherapy. Multiagent regimens increase toxicity without clear benefit; however, no preferred sequence of single agents is recommended. The impact of targeted therapies and immunotherapies on progression-free survival and overall survival, which remains dismal, is under active investigation. Currently, clinical trials offer the best hope for the development of a new treatment paradigm in this recalcitrant disease.

AB - Ovarian cancer, which ranks fifth in cancer deaths among women, is the most lethal gynecologic malignancy. Epithelial ovarian cancer (EOC) is the most common histologic type, with the 5-year survival for all stages estimated at 45.6%. This rate increases to more than 70% in the minority of patients who are diagnosed at an early stage, but declines to 35% in the vast majority of patients diagnosed at advanced stage. Recurrent EOC is incurable. Platinum sensitivity (or lack thereof) is a major determinant of prognosis. The current standard treatment is primary surgery followed by platinum-based chemotherapy. In recurrent platinum-resistant/platinum-refractory EOC, sequential single-agent salvage chemotherapy is superior to multiagent chemotherapy. Multiagent regimens increase toxicity without clear benefit; however, no preferred sequence of single agents is recommended. The impact of targeted therapies and immunotherapies on progression-free survival and overall survival, which remains dismal, is under active investigation. Currently, clinical trials offer the best hope for the development of a new treatment paradigm in this recalcitrant disease.

KW - Epigenetic

KW - Epithelial ovarian cancer

KW - Platinum refractory

KW - Platinum resistant

KW - VEGF inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85018834485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018834485&partnerID=8YFLogxK

U2 - 10.1007/s12032-017-0960-z

DO - 10.1007/s12032-017-0960-z

M3 - Review article

C2 - 28444622

AN - SCOPUS:85018834485

VL - 34

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 6

M1 - 103

ER -